We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

Canada’s regulation of subsequent entry biologics
  • Torys LLP
  • Canada
  • April 6 2009

Health Canada has released a revised version of the draft guidance document "Information and Submission Requirements for Subsequent Entry Biologics."


Data protection for drug innovators comes under attack
  • Torys LLP
  • Canada
  • March 10 2010

A decision released by the Federal Court of Appeal in Minister of Health v. Merck Frosst Canada Ltd. represents a blow to innovative drug manufacturers under Canada’s access to information regime


Canada's approach to functional foods
  • Torys LLP
  • Canada
  • April 21 2010

Today’s diet- and health-conscious environment has led to a proliferation of functional food marketing claims that advertise the specific health-enhancing characteristics of a food product


Ontario case on product liability shows the immense scope of a class action trial
  • Torys LLP
  • Canada
  • July 5 2012

In a highly anticipated decision released on June 26, 2012, the Ontario Superior Court of Justice ruled in favour of the defendants in Andersen v. St. Jude Medical, Inc., Ontario’s first medical product liability class action trial


Supreme Court of Canada rules on data protection for drug innovators
  • Torys LLP
  • Canada
  • February 8 2012

On February 3, 2012, the Supreme Court of Canada released its long-awaited decision in Merck Frosst Canada Ltd. v. Canada (Health), the culmination of over a decade of litigation between Merck and the Minister of Health


Ontario court confirms generic drug manufacturers not entitled to unjust enrichment
  • Torys LLP
  • Canada
  • January 22 2013

On January 15, 2013, the Ontario Superior Court of Justice (Ontario Court) granted a motion for partial summary judgment in Apotex Inc. v. Abbott


Canada’s PAAB releases updated Code of Advertising Acceptance
  • Torys LLP
  • Canada
  • December 7 2012

The Pharmaceutical Advertising Advisory Board (PAAB) has released a revised version of its Code of Advertising Acceptance


Proposed amendments to the Patented Medicines (Notice of Compliance) Regulations
  • Torys LLP
  • Canada
  • April 29 2008

On April 26, 2008, the government of Canada published for comment proposed amendments to the Patented Medicines (Notice of Compliance) Regulations, commonly referred to as the “PM(NOC) Regulations.”


Canada proposes amending the Food and Drugs Act and creating consumer product safety legislation
  • Torys LLP
  • Canada
  • May 2 2008

On April 8, 2008, the federal government tabled legislation in the House of Commons to amend the Food and Drugs Act and to introduce new consumer product safety legislation in Canada


Ontario government seeks appeal of pharmacies' successful challenge on private label restrictions
  • Torys LLP
  • Canada
  • February 24 2011

The regulation of private label drug products remains in flux with the recent decision of the Ontario Superior Court of Justice (Divisional Court) and potential appeal of that decision